| First Author | Raza A | Year | 2017 |
| Journal | J Leukoc Biol | Volume | 102 |
| Issue | 5 | Pages | 1219-1227 |
| PubMed ID | 28877953 | Mgi Jnum | J:247818 |
| Mgi Id | MGI:5925893 | Doi | 10.1189/jlb.2AB0116-009RR |
| Citation | Raza A, et al. (2017) Anti-inflammatory roles of p38alpha MAPK in macrophages are context dependent and require IL-10. J Leukoc Biol 102(5):1219-1227 |
| abstractText | The p38 MAPK pathway was originally identified as a master regulator of proinflammatory cytokine production by myeloid cells. Numerous drugs targeting this kinase showed promise in preclinical models of inflammatory disease, but so far, none have shown efficacy in clinical trials. The reasons behind this are unclear, but may, in part, be explained by emerging anti-inflammatory functions of this kinase or overly refined selectivity of second-generation pharmacologic inhibitors. Here, we show that p38alpha signaling in macrophages plays pro- and anti-inflammatory functions in vivo and in vitro, with the outcome depending on the stimulus, output, kinetics, or mode of kinase inhibition (genetic vs. pharmacologic). Different pharmacologic inhibitors of p38 exhibit opposing effects, with second-generation inhibitors acting more specifically but inhibiting anti-inflammatory functions. Functionally, we show that the anti-inflammatory functions of p38alpha in macrophages are critically dependent on production of IL-10. Accordingly, in the absence of IL-10, inhibition of p38alpha signaling in macrophages is protective in a spontaneous model of colitis. Taken together, our results shed light on the limited clinical efficacy of drugs targeting p38 and suggest that their therapeutic efficacy can be significantly enhanced by simultaneous modulation of p38-dependent anti-inflammatory mediators, such as IL-10. |
